作者:Louis Jeanne-Julien、Guillaume Masson、Eloi Astier、Grégory Genta-Jouve、Vincent Servajean、Jean-Marie Beau、Stéphanie Norsikian、Emmanuel Roulland
DOI:10.1021/acs.orglett.7b01744
日期:2017.8.4
with a new biological target, giving it an inestimable potential in the context of the ever-growing and worrisome appearance of resistances of bacteria and mycobacteria to antibiotics. The synthesis of an aglycone of tiacumicin B ready for glycosylation is reported. The key steps of this approach are a [2,3]-Wittig rearrangement, a Pd/Cu-catalyzed allene–alkyne cross-coupling, a E-selective cross-metathesis
Tiacumicin B是一种具有与新的生物靶标相互作用的显着能力的抗生素,在细菌和分枝杆菌对抗生素的耐药性日益增长且令人担忧的情况下,使其具有不可估量的潜力。报道了准备用于糖基化的头孢菌素B糖苷配基的合成。该方法的关键步骤是[2,3] -Wittig重排,Pd / Cu催化的丙二烯-炔烃交叉偶联,E选择性交叉复分解和最终的环尺寸选择性大环内酯化。